The value of combined detection of HbA2 and HbF for the screening of thalassemia among individuals of childbearing ages.
10.3760/cma.j.cn 511374-20210202-00104
- Author:
Qianmei ZHUANG
1
;
Geng WANG
;
Yuanbai WANG
;
Jianlong ZHUANG
;
Yuying JIANG
;
Hailong HUANG
;
Liangpu XU
Author Information
1. Prenatal Diagnosis Center, Quanzhou Women's and Children's Hospital, Quanzhou, Fujian 362017, China. ipxiu304@126.com.
- Publication Type:Journal Article
- MeSH:
Genotype;
Hemoglobin A2/genetics*;
Heterozygote;
Humans;
Mass Screening;
Mutation;
alpha-Thalassemia;
beta-Thalassemia/genetics*
- From:
Chinese Journal of Medical Genetics
2022;39(1):16-20
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the application value of combined detection of HbA2 and HbF for the screening of thalassemia among a population of childbearing age in Quanzhou, Fujian, and determine the optimal cut-off values for the region.
METHODS:Capillary hemoglobin electrophoresis and genetic testing for α and β globin gene mutations were simultaneously carried out on 11 428 patients with suspected thalassemia. Statistical methods were used to analyze the distribution of various types of thalassemia and compare the performance of HbA2 and HbF measurement for the screening of various types of thalassemia. The optimal cut-off values for HbA2 and HbF were determined with the ROC curves.
RESULTS:4591 patients with α, β, and αβ compound thalassemia were identified by genetic testing. The most common genotypes for α and β thalassemia included --SEA/αα and β654/βN, β41-42/βN, and β17/βN. The ROC curves were drawn to compare the performance of HbA2 screening for α-, β-, αβ-compound, static α-, mild α-, and intermediate α-thalassemia, and the maximum area under the curves was 0.674, 0.984, 0.936, 0.499, 0.731, 0.956, and the optimal cut-off values for HbA2 were 2.45%, 3.25%, 3.65%, 2.95%, 2.55%, 1.75%, respectively.
CONCLUSION:HbA2 is an efficient indicator for identifying intermediate types of α-, β-, and αβ compound thalassemia. The combination of HbA2 and HbF measurement can effectively detect carriers for β-thalassemia mutations.
